NEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
NeoGenomics Inc. (NEO) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock shows no immediate bullish signals from technical indicators, options data, or proprietary trading signals. While the company has demonstrated revenue growth and improving net income, the negative EPS and declining gross margin are concerning. Analysts have a mixed view, with some optimism for 2026, but the current pre-market price trend and lack of positive catalysts suggest waiting for a clearer entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is at 26.266, which is neutral but nearing oversold territory. Moving averages are converging, showing no clear trend. Key support is at $11.238, with resistance at $12.426. The stock has a 60% chance to decrease by -0.53% in the next day and -6.42% in the next month.
Analysts expect solid results for the diagnostics sector in 2026, with headwinds expected to fade and biopharma spending to return.
Net income remains negative at -$27.13M despite improvement. Gross margin dropped by -3.99% YoY. No recent news or significant insider/hedge fund trading activity. Technical indicators and stock trend analysis suggest bearish momentum in the short term.
In Q3 2025, revenue increased to $187.8M (+11.90% YoY), net income improved to -$27.13M (+53.28% YoY), and EPS increased to -0.21 (+50% YoY). However, gross margin declined to 42.84% (-3.99% YoY).
Analysts have mixed views. TD Cowen raised the price target to $16 and maintains a Buy rating, citing strong fundamentals. BofA raised the price target to $13 but maintains a Neutral rating, expecting headwinds to fade and biopharma spending to return in 2026.
